A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

ClinicalTrials.gov ID: NCT07187973

Public ClinicalTrials.gov record NCT07187973. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-3405 in Participants With Sickle Cell Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

Study identification

NCT ID: NCT07187973
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Disc Medicine, Inc; Industry
Enrollment: 24 participants

Conditions and interventions

Conditions

Sickle Cell Disease

Interventions

DISC-3405 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 6, 2026 (Actual)
Primary completion: Jun 2027 (Estimated)
Completion: Oct 2027 (Estimated)
Last update posted: Oct 5, 2026

2026 – 2027

United States locations

U.S. sites: 11
U.S. states: 9
U.S. cities: 11

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294	Recruiting
University of California San Francisco (UCSF) Medical Center	San Francisco	California	94143	Recruiting
Emory University	Atlanta	Georgia	30322	Recruiting
Augusta University	Augusta	Georgia	30912	Recruiting
University of Illinois Hospital and Health Sciences System	Chicago	Illinois	60612	Recruiting
Innovative Hematology - Indiana Hemophilia & Thrombosis Center	Indianapolis	Indiana	46260	Recruiting
Mount Sinai Hospital	New York	New York	10029	Recruiting
Duke University Medical Center	Durham	North Carolina	27708	Recruiting
Brody School of Medicine at East Carolina University	Greenville	North Carolina	27834	Recruiting
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	45229	Recruiting
University of Pittsburgh Medical Center (UPMC)	Pittsburgh	Pennsylvania	15213	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07187973, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 5, 2026 · Synced Nov 6, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07187973 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →